Fair Value Measurements - Financial Instruments at Fair Value (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended			12 Months Ended
	Mar. 27, 2017	Apr. 01, 2017	Apr. 02, 2016	Jul. 01, 2017		Jul. 02, 2016	Dec. 31, 2016		Oct. 02, 2016	Apr. 03, 2016	Dec. 31, 2015
Assets:
Financial asset				$ 0.0			$ 2,350.0
Indefinite-lived intangible assets(2)									$ 674.2	$ 364.5
Liabilities:
Indefinite-lived intangibles carrying amount				102.7			114.5
Finite-lived intangible assets				4,573.7			4,417.2
Proceeds from sale of business and other assets				37.2		$ 0.0
Measured at fair value on a recurring basis: | Level 1
Assets:
Investment securities				13.6			38.2
Measured at fair value on a recurring basis: | Level 2
Assets:
Foreign currency forward contracts				16.6			3.8
Funds associated with Israeli severance liability				18.1			15.9
Total level 3 assets				34.7			19.7
Liabilities:
Foreign currency forward contracts				4.0			5.0
Measured at fair value on a recurring basis: | Level 3
Assets:
Financial asset				0.0			2,350.0
Total level 3 assets				145.8			2,350.0
Measured at fair value on a non-recurring basis: | Level 3
Assets:
Goodwill(1)				0.0			1,148.4	[1]
Indefinite-lived intangible assets(2)		$ 13.8		13.8	[2]		0.3	[2]
Definite-lived intangible assets(3)				11.5			758.0	[3]
Assets held for sale, net				11.8			18.2
Total level 3 assets				37.1			1,924.9
Liabilities:
Goodwill							2,200.0
Indefinite-lived intangibles carrying amount		26.0					0.7
Impairment of intangible assets		12.2
Definite lived asset impairment				19.6
Contingent consideration | Measured at fair value on a recurring basis: | Level 3
Liabilities:
Contingent consideration		52.0		49.7		$ 44.9	69.9			$ 48.0	$ 17.9
Accounts Receivable [Member] | Measured at fair value on a recurring basis: | Level 3
Assets:
Royalty Pharma contingent milestone payments				$ 145.8			0.0
Liabilities:
Contingent consideration		$ 184.5					0.0
CHCI
Liabilities:
Finite-lived intangible assets							2,300.0
Omega | Brands
Liabilities:
Impairment of intangible assets			$ 273.4
Definite lived asset impairment							$ 1,500.0
Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sale price of divestiture - cash plus non-cash	$ 2,850.0
Liabilities:
Proceeds from sale of business and other assets	2,200.0
Contingent Proceeds from Divestiture of Business, Milestone One, Maximum	250.0
Contingent Proceeds from Divestiture of Business, Milestone Two, Maximum	$ 400.0

[1] (1) As of December 31, 2016, goodwill with a carrying amount of $2.2 billion was written down to its implied fair value of $1.1 billion

[2] (2) As of April 1, 2017, indefinite-lived intangible assets with a carrying amount of $26.0 million were written down to a fair value of $13.8 million, resulting in a total impairment charge of $12.2 million. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of $0.7 million were written down to a fair value of $0.3 million.

[3] (3) As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million, resulting in a total impairment charge of $19.6 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million, resulting in a total impairment charge of $1.5 billion. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.